Chemical Structure (Vizimpro 01)
Vizimpro Tablet, Film Coated
Product Images NDC 0069-0197
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Vizimpro (NDC 0069-0197). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Vizimpro 02)
This appears to be a graph or chart displaying the "Probability of Progression-Free Survival" for two different medications, VIZIMPRO and Geftino. The numbers in the chart represent the number of patients who have progressed or who remain progression-free over a certain number of months. There are also a few values at the base of the chart, but without more context it is difficult to determine their significance.*
Figure 2 (Vizimpro 03)
This appears to be a chart or table showing the overall survival rates for individuals taking two different medications: vizmPRO and Gefitinib. The chart displays the number of individuals at risk and the number of months they survived while taking each medication. The values at the base of the figure indicate the number of patients at risk. There are also some consored patents, which are presumably censored data points.*
Logo (Vizimpro 04)
This is a description of the distributor of a product manufactured by Pfizer Inc, NY, NY 10017. The distributor is Pfizer Labs, which is a division of Pfizer Inc.*
Logo (Vizimpro 05)
This text indicates that Pfizer Labs, which is a division of Pfizer Inc. located in New York City, is responsible for the distribution of a certain product or products. However, without additional context, it is not clear what specific product or products are being referred to.*
Principal Display Panel (15 mg Tablet Bottle Label)
Store the medication containing dacomitinib tablets at a temperature between 20°C to 25°C (68°F to 77°F). Excursions to a temperature range of 15°C to 30°C (59°F to 86°F) are allowed. The medicine should be dispensed in tight bags that meet USP standards. The tablets are for oral administration only, and the dosage and other information should be read with the prescription. Each tablet contains 15 mg dacomitinib. This medication is distributed by Pfizer Labs, a division of Pfizer Inc, New York. The label also mentions that the product is made in Ireland and that there are 30 tablets in each pack, available through prescription only.*
Principal Display Panel (30 mg Tablet Bottle Label)
Store this medication at a temperature between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (50°F to 86°F). The medication Vizimpro contains dacomitinib tablets and each tablet has a dosage of 30 mg. Please refer to the accompanying prescribing information for usage guidelines. The medication is distributed by Pfizer Labs in New York and each box contains 30 tablets. The product was made in Ireland and has a UPC code of 00300691198308.*
Principal Display Panel (45 mg Tablet Bottle Label)
Store dacomitinib tablets at a temperature range of 20°C to 25°C (68°F to 77°F) with excursions allowed between 15°C and 30°C (50°F to 86°F). Each tablet contains 45 mg of dacomitinib and is distributed by Pfizer Labs, a division of Pfizer Inc. This medication is used for a specific purpose, so refer to the accompanying prescribing information before use. The product contains 30 tablets and can only be obtained through a prescription. The rest of the text is not informative.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
